Spero Therapeutics, Inc. (SPRO) — Financial statements
Income statement, balance sheet, and cash flow for Spero Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 60↑24.3% | 48↓53.8% | 104↑113.6% | 49↑1482.4% | 3 | |
| Cost of Revenue | 0.00↓100.0% | 97↑88.1% | 51 | 0.00 | 0.00 | |
| Gross Profit | 60↑222.2% | -49↓193.2% | 52↑7.7% | 49↑1482.4% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↓60.2% | 97↑88.1% | 51↑8.1% | 48↓26.2% | 65 | |
| General & Administrative Expenses | 21↓7.6% | 23↓8.3% | 25↓31.5% | 36↓12.5% | 42 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.79↑39.9% | 0.57 | 0.00 | 0.00 | |
| SG&A Expenses | 21↓10.7% | 24↓7.2% | 26↓30.0% | 36↓12.5% | 42 | |
| Other Expenses | 0.00↑100.0% | -96↓107.8% | -46↓788.6% | 7↑144.1% | -15 | |
| Operating Expenses | 60↑142.6% | 25↓20.3% | 31↓66.0% | 91↓0.3% | 91 | |
| Total Costs & Expenses | 60↓50.8% | 121↑47.4% | 82↓9.3% | 91↓0.3% | 91 | |
| Operating Results | ||||||
| Operating Income | -0.02↑100.0% | -73↓441.5% | 21↑150.9% | -42↑52.0% | -88 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.00↓99.5% | 0.37↓57.8% | 0.87↑34.5% | 0.65 | |
| EBITDA | -0.02↑100.0% | -72↓366.9% | 27↑163.2% | -43↑50.7% | -87 | |
| EBIT | -0.02↑100.0% | -72↓370.6% | 27↑161.1% | -44↑50.1% | -88 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓46.9% | 5↑20.3% | 4↑362.6% | -1↑6.0% | -2 | |
| Interest Income | 3↓46.9% | 5↑20.3% | 4↑256.0% | 1↑219.7% | 0.35 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 3↑34.3% | 2 | |
| Non-Operating Income | 0.00↑100.0% | -0.88↑83.5% | -5↓429.0% | 2↑1140.6% | -0.16 | |
| Other Income / Expenses | 9↑84.7% | 5↑22.2% | 4↑193.0% | -4↓136.3% | -2 | |
| Income Before Tax | 9↑112.9% | -69↓369.9% | 25↑154.7% | -46↑48.3% | -90 | |
| Income Tax Expense | 0.26 | 0.00↓100.0% | 3 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 9↑112.5% | -69↓400.6% | 23↑149.1% | -46↑48.3% | -90 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 9↑112.5% | -69↓400.6% | 23↑149.1% | -46↑48.3% | -90 | |
| Bottom-Line Net Income | 9↑112.5% | -69↓400.6% | 23↑149.1% | -46↑48.3% | -90 | |
| EPS (Basic) | 0.15↑111.8% | -1.27↓395.3% | 0.43↑135.0% | -1.23↑57.7% | -2.91 | |
| EPS (Diluted) | 0.15↑111.8% | -1.27↓395.3% | 0.43↑135.0% | -1.23↑57.7% | -2.91 | |
| Weighted Average Shares | 56↑3.7% | 54↑2.5% | 53↑40.2% | 38↑21.7% | 31 | |
| Weighted Average Diluted Shares | 59↑9.3% | 54↑2.0% | 53↑41.0% | 38↑21.7% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.